LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) announced the US FDA approved the company's supplemental New Drug Application for Zejula (niraparib), a poly polymerase inhibitor, as a monotherapy maintenance treatment for women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, regardless of biomarker status.
Hal Barron, President R&D, GSK, said: 'Women with advanced ovarian cancer have a five-year survival rate of less than 50%. This expanded indication means that many more women with this devastating disease can receive earlier treatment with Zejula, which can extend the time it takes for their cancer to progress.'
Copyright RTT News/dpa-AFX
© 2020 AFX News
